Anti-cancer drug KP1019 modulates epigenetics and induces DNA damage response in Saccharomyces cerevisiae

FEBS Letters

Volumn 588, Issue 6, 2014, Pages 1044-1052

  Singh, Vikash ^a   Azad, Gajendra Kumar ^a   Mandal, Papita ^a   Amarendar Reddy, M ^a   Tomar, Raghuvir S ^a  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH BHOPAL   (India)

Author keywords

Anti cancer drug; DNA damage response; Epigenetics; Histones; KP1019

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 2; DUN1 CHECKPOINT KINASE; FUNGAL PROTEIN; HISTONE H3; INDAZOLIUM TETRACHLOROBIS(INDAZOLE)RUTHENATE; MEC1 CHECKPOINT KINASE; PROTEIN SERINE THREONINE KINASE; RIBONUCLEOTIDE REDUCTASE; RNR1 PROTEIN; RNR2 PROTEIN; RUTHENIUM DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CHROMATIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA DAMAGE CHECKPOINT; DNA HISTONE INTERACTION; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME DEGRADATION; EPIGENETICS; EUKARYOTE; FUNGAL GENE; FUNGUS GROWTH; FUNGUS MUTANT; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE REPLICATION; GENETIC REGULATION; GROWTH INHIBITION; HISTONE ACETYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBONUCLEOTIDE REDUCTASE GENE; SACCHAROMYCES CEREVISIAE; UPREGULATION; YEAST CELL;

ANTI-CANCER DRUG; DNA DAMAGE RESPONSE; EPIGENETICS; HISTONES; KP1019;

ANTINEOPLASTIC AGENTS; CHROMATIN; DNA DAMAGE; DNA REPAIR; DRUG SCREENING ASSAYS, ANTITUMOR; EPIGENESIS, GENETIC; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE EXPRESSION REGULATION, FUNGAL; HISTONE DEACETYLASES; HISTONES; HUMANS; INDAZOLES; MICROBIAL VIABILITY; ORGANOMETALLIC COMPOUNDS; PROTEIN PROCESSING, POST-TRANSLATIONAL; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS;

SACCHAROMYCES CEREVISIAE;

EID: 84896071887     PISSN: 00145793     EISSN: 18733468     Source Type: Journal    
DOI: 10.1016/j.febslet.2014.02.017     Document Type: Article

References (57)

1. Z.H. Siddik Cisplatin: mode of cytotoxic action and molecular basis of resistance Oncogene 22 2003 7265 7279
2. P.J. Dyson, and G. Sava Metal-based antitumour drugs in the post genomic era Dalton Trans. 2006 1929 1933
3. T.W. Hambley The influence of structure on the activity and toxicity of Pt anti-cancer drugs Coord. Chem. Rev. 166 1997 181 223
4. A. Galeano, M.R. Berger, and B.K. Keppler Antitumor-activity of some ruthenium derivatives in human colon cancer cell-lines in vitro Arzneim.-Forsch./Drug Res. 42-1 1992 821 824
5. M.R. Berger, F.T. Garzon, B.K. Keppler, and D. Schmahl Efficacy of new ruthenium complexes against chemically-induced autochthonous colorectal-carcinoma in rats Anticancer Res. 9 1989 761 765
6. G. Sava, and A. Bergamo Ruthenium-based compounds and tumour growth control (Review) Int. J. Oncol. 17 2000 353 365
7. M.H. Seelig, M.R. Berger, and B.K. Keppler Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats J. Cancer Res. Clin. Oncol. 118 1992 195 200
8. V. Brabec DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair Prog. Nucleic Acid Res. Mol. Biol. 71 71 2002 1 68
9. C.G. Hartinger et al. KP1019, A new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients Chem. Biodivers. 5 2008 2140 2155
10. P. Heffeter et al. Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 J. Biol. Inorg. Chem. 15 2010 737 748
11. P. Heffeter et al. Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans-[tetrachlorobis(1H- indazole)ruthenate(III)] (FFC14A) J. Pharmacol. Exp. Ther. 312 2005 281 289
12. M. Pongratz, P. Schluga, M.A. Jakupec, V.B. Arion, C.G. Hartinger, G. Allmaier, and B.K. Keppler Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy J. Anal. At. Spectrom. 19 2004 46 51
13. F. Kratz, M. Hartmann, B. Keppler, and L. Messori The binding properties of two antitumor ruthenium(III) complexes to apotransferrin J. Biol. Chem. 269 1994 2581 2588
14. S.K. Stevens et al. The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae Mol. Pharmacol. 83 2013 225 234
15. G.K. Azad, V. Singh, U. Golla, and R.S. Tomar Depletion of cellular iron by curcumin leads to alteration in histone acetylation and degradation of Sml1p in Saccharomyces cerevisiae PLoS ONE 8 2013 e59003
16. K.G. Lipponer, E. Vogel, and B.K. Keppler Synthesis, characterization and solution chemistry of trans-indazoliumtetrachlorobis(indazole)ruthenate(III), a new anticancer ruthenium complex. IR, UV, NMR, HPLC investigations and antitumor activity. Crystal structures of trans-1-methyl- indazoliumtetrachlorobis-(1-methylindazole)ruthenate(III) and its hydrolysis product trans-monoaquatrichlorobis-(1-methylindazole)-ruthenate(III) Met. Based Drugs 3 1996 243 260
17. J.B. Aitken, S. Antony, C.M. Weekley, B. Lai, L. Spiccia, and H.H. Harris Distinct cellular fates for KP1019 and NAMI-A determined by X-ray fluorescence imaging of single cells Metallomics 4 1051-6 2012 1007
18. P. Mandal, G.K. Azad, and R.S. Tomar Identification of a novel histone H3 specific protease activity in nuclei of chicken liver Biochem. Biophys. Res. Commun. 421 2012 261 267
19. G.K. Azad, S.J. Balkrishna, N. Sathish, S. Kumar, and R.S. Tomar Multifunctional Ebselen drug functions through the activation of DNA damage response and alterations in nuclear proteins Biochem. Pharmacol. 83 2012 296 303
20. S.J. Balkrishna et al. An ebselen like catalyst with enhanced GPx activity via a selenol intermediate Org. Biomol. Chem. 12 2014 1215 1219
21. G.K. Azad, V. Singh, P. Mandal, P. Singh, U. Golla, S. Baranwal, S. Chauhan, and R.S. Tomar Ebselen induces reactive oxygen species (ROS)-mediated cytotoxicity in Saccharomyces cerevisiae with inhibition of glutamate dehydrogenase being a target FEBS Open Bio 4 2014 77 89
22. U. Golla, V. Singh, G.K. Azad, P. Singh, N. Verma, P. Mandal, S. Chauhan, and R.S. Tomar Sen1p contributes to genomic integrity by regulating expression of ribonucleotide reductase 1 (RNR1) in Saccharomyces cerevisiae PLoS ONE 8 2013 e64798
23. B. Wu, M.S. Ong, M. Groessl, Z. Adhireksan, C.G. Hartinger, P.J. Dyson, and C.A. Davey A ruthenium antimetastasis agent forms specific histone protein adducts in the nucleosome core Chem. Eur. J. 17 2011 3562 3566
24. J. Han, H. Zhou, B. Horazdovsky, K. Zhang, R.M. Xu, and Z. Zhang Rtt109 acetylates histone H3 lysine 56 and functions in DNA replication Science 315 2007 653 655
25. R. Driscoll, A. Hudson, and S.P. Jackson Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine 56 Science 315 2007 649 652
26. J.A. Kim, J.Y. Hsu, M.M. Smith, and C.D. Allis Mutagenesis of pairwise combinations of histone amino-terminal tails reveals functional redundancy in budding yeast Proc. Natl. Acad. Sci. U.S.A. 109 2012 5779 5784
27. V. Morales, and H. Richard-Foy Role of histone N-terminal tails and their acetylation in nucleosome dynamics Mol. Cell. Biol. 20 2000 7230 7237
28. X.L. Zhao, A. Chabes, V. Domkin, L. Thelander, and R. Rothstein The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage EMBO J. 20 2001 3544 3553
29. X. Zhao, and R. Rothstein The Dun1 checkpoint kinase phosphorylates and regulates the ribonucleotide reductase inhibitor Sml1 Proc. Natl. Acad. Sci. U.S.A. 99 2002 3746 3751
30. B.L. Andreson, A. Gupta, B.P. Georgieva, and R. Rothstein The ribonucleotide reductase inhibitor, Sml1, is sequentially phosphorylated, ubiquitylated and degraded in response to DNA damage Nucleic Acids Res. 38 2010 6490 6501
31. M. Frank-Vaillant, and S. Marcand Transient stability of DNA ends allows nonhomologous end joining to precede homologous recombination Mol. Cell 10 2002 1189 1199
32. P.C. Hanawalt Subpathways of nucleotide excision repair and their regulation Oncogene 21 2002 8949 8956
33. P.C. Hanawalt, and G. Spivak Transcription-coupled DNA repair: two decades of progress and surprises Nat. Rev. Mol. Cell Biol. 9 2008 958 970
34. Y. Aylon, and M. Kupiec DSB repair: the yeast paradigm DNA Repair 3 2004 797 815
35. Y. Bai, and L.S. Symington A Rad52 homolog is required for RAD51-independent mitotic recombination in Saccharomyces cerevisiae Genes Dev. 10 1996 2025 2037
36. U.H. Mortensen, C. Bendixen, I. Sunjevaric, and R. Rothstein DNA strand annealing is promoted by the yeast Rad52 protein Proc. Natl. Acad. Sci. U.S.A. 93 1996 10729 10734
37. C.A. Parsons, P. Baumann, E. Van Dyck, and S.C. West Precise binding of single-stranded DNA termini by human RAD52 protein EMBO J. 19 2000 4175 4181
38. A.Z. Stasiak, E. Larquet, A. Stasiak, S. Muller, A. Engel, E. Van Dyck, S.C. West, and E.H. Egelman The human Rad52 protein exists as a heptameric ring Curr. Biol. 10 2000 337 340
39. A. Shinohara, M. Shinohara, T. Ohta, S. Matsuda, and T. Ogawa Rad52 forms ring structures and co-operates with RPA in single-strand DNA annealing Genes Cells 3 1998 145 156
40. C.G. Hartinger, S. Zorbas-Seifried, M.A. Jakupec, B. Kynast, H. Zorbas, and B.K. Keppler From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H- indazole)ruthenate(III)] (KP1019 or FFC14A) J. Inorg. Biochem. 100 2006 891 904
41. P. Heffeter et al. Resistance against novel anticancer metal compounds: differences and similarities Drug Resist. Updates 11 2008 1 16
42. D. Chen, L. Fang, H. Li, M.S. Tang, and C. Jin Cigarette smoke component acrolein modulates chromatin assembly by inhibiting histone acetylation J. Biol. Chem. 288 2013 21678 21687
43. B. Pang et al. Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin Nat. Commun. 4 2013 1908
44. U.J. Kim, M. Han, P. Kayne, and M. Grunstein Effects of histone-H4 depletion on the cell-cycle and transcription of Saccharomyces cerevisiae EMBO J. 7 1988 2211 2219
45. Q. Li, H. Zhou, H. Wurtele, B. Davies, B. Horazdovsky, A. Verreault, and Z.G. Zhang Acetylation of histone H3 lysine 56 regulates replication-coupled nucleosome assembly Cell 134 2008 244 255
46. J.H. Seol, H.J. Kim, J.K. Yoo, H.J. Park, and E.J. Cho Analysis of Saccharomyces cerevisiae histone H3 mutants reveals the role of the alpha N helix in nucleosome function Biochem. Biophys. Res. Commun. 374 2008 543 548
47. L.V. Minard, J.S. Williams, A.C. Walker, and M.C. Schultz Transcriptional regulation by Asf1: new mechanistic insights from studies of the DNA damage response to replication stress J. Biol. Chem. 286 2011 7082 7092
48. Q. Li, H. Zhou, H. Wurtele, B. Davies, B. Horazdovsky, A. Verreault, and Z. Zhang Acetylation of histone H3 lysine 56 regulates replication-coupled nucleosome assembly Cell 134 2008 244 255
49. S. Kapitza, M.A. Jakupec, M. Uhl, B.K. Keppler, and B. Marian The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells Cancer Lett. 226 2005 115 121
50. S. Fruhauf, and W.J. Zeller New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor-cells Cancer Res. 51 1991 2943 2948
51. Y.N. Vashisht Gopal, and A.K. Kondapi Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium J. Biosci. 26 2001 271 276
52. J.S. Liu, S.R. Kuo, and T. Melendy Comparison of checkpoint responses triggered by DNA polymerase inhibition versus DNA damaging agents Mutat. Res. 532 2003 215 226
53. L.C. Tu, S.I. Matsui, and T.A. Beerman Hedamycin, a DNA alkylator, induces (gamma)H2AX and chromosome aberrations: involvement of phosphatidylinositol 3-kinase-related kinases and DNA replication fork movement Mol. Cancer Ther. 4 2005 1175 1185
54. C. Ramachandran, T.S. Samy, X.L. Huang, Z.K. Yuan, and A. Krishan Doxorubicin-induced DNA breaks, topoisomerase II activity and gene expression in human melanoma cells Biochem. Pharmacol. 45 1993 1367 1371
55. L. Gianni, E.H. Herman, S.E. Lipshultz, G. Minotti, N. Sarvazyan, and D.B. Sawyer Anthracycline cardiotoxicity: from bench to bedside J. Clin. Oncol. 26 2008 3777 3784
56. K. Cho, H.W. Shin, Y.I. Kim, C.H. Cho, Y.S. Chun, T.Y. Kim, and J.W. Park Mad1 mediates hypoxia-induced doxorubicin resistance in colon cancer cells by inhibiting mitochondrial function Free Radical Biol. Med. 60 2013 201 210
57. C. Riganti, E. Miraglia, D. Viarisio, C. Costamagna, G. Pescarmona, D. Ghigo, and A. Bosia Nitric oxide reverts the resistance to doxorubicin in human colon cancer cells by inhibiting the drug efflux Cancer Res. 65 2005 516 525